Showing 1,141 - 1,160 results of 105,020 for search '(( 12 mean decrease ) OR ( 5 ((nn decrease) OR (((teer decrease) OR (a decrease)))) ))', query time: 1.33s Refine Results
  1. 1141
  2. 1142

    Flowchart of patients. by Seydou Goro (17847203)

    Published 2024
    “…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”
  3. 1143

    Baseline characteristics of patients. by Seydou Goro (17847203)

    Published 2024
    “…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”
  4. 1144
  5. 1145
  6. 1146

    rVλ6Wil fibrils cause oxidative stress in cardiomyocytes without a decrease in cellular ATP. by Helen P. McWilliams-Koeppen (116503)

    Published 2015
    “…<p>(A) After a 2 h incubation with rVλ6Wil fibrils or monomer, cellular ATP levels, as detected by luminescence (black bars), were not significantly reduced relative to the PBS-treated control. …”
  7. 1147
  8. 1148
  9. 1149
  10. 1150
  11. 1151
  12. 1152
  13. 1153
  14. 1154

    Changes in TEER and permeability of EA.hy926 cells exposed to EVs or pellets from infected or uninfected macrophages. by Myriam Lucia Velandia-Romero (8259726)

    Published 2020
    “…<p>(A). The EA.hy926 cells seeded on transwell® inserts showed a TEER of 25 Ω/Cm<sup>2</sup> at time 0. …”
  15. 1155
  16. 1156

    Inhibition of IL-17A at tumor sites decreases the intratumoral microvessel density. by Keiji Hayata (277090)

    Published 2013
    “…<p>(A) The endothelial maker CD31-stained sections of tumor tissue are shown in Ad-SNC and Ad-si-IL-17 treatment models, Ad-si-IL-17 treatment decreased the intratumoral microvessel density compared with Ad-SNC. …”
  17. 1157
  18. 1158

    Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retr... by Wendy C. Moore (10682686)

    Published 2025
    “…The proportion of patients with both no exacerbations and no OCS use progressively increased from 6.4% at baseline to 18.5% at Year 1 and 41.8% at Year 4. Exacerbation-related HCRU including inpatient, emergency room, and outpatient office visits decreased from baseline (9.0%, 21.7%, and 78.8%, respectively), at Year 1 (3.2%, 12.2%, and 49.2%), and Year 4 (0.0%, 4.8%, and 31.8%). …”
  19. 1159
  20. 1160